MX379513B - Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. - Google Patents
Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.Info
- Publication number
- MX379513B MX379513B MX2018011992A MX2018011992A MX379513B MX 379513 B MX379513 B MX 379513B MX 2018011992 A MX2018011992 A MX 2018011992A MX 2018011992 A MX2018011992 A MX 2018011992A MX 379513 B MX379513 B MX 379513B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- aminopurine compounds
- treatment therewith
- substituted aminopurine
- Prior art date
Links
- -1 aminopurine compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317412P | 2016-04-01 | 2016-04-01 | |
| PCT/US2017/025252 WO2017173206A1 (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018011992A MX2018011992A (es) | 2019-01-24 |
| MX379513B true MX379513B (es) | 2025-03-11 |
Family
ID=59959573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011992A MX379513B (es) | 2016-04-01 | 2017-03-31 | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10576085B2 (enExample) |
| EP (1) | EP3436018A4 (enExample) |
| JP (1) | JP7014731B2 (enExample) |
| KR (1) | KR102356433B1 (enExample) |
| CN (1) | CN109069512B (enExample) |
| AU (1) | AU2017241837B2 (enExample) |
| BR (1) | BR112018070163A2 (enExample) |
| CA (1) | CA3018986A1 (enExample) |
| CL (1) | CL2018002787A1 (enExample) |
| EA (1) | EA039392B1 (enExample) |
| IL (1) | IL262007B2 (enExample) |
| MX (1) | MX379513B (enExample) |
| NZ (1) | NZ746554A (enExample) |
| SG (2) | SG10202009589UA (enExample) |
| WO (1) | WO2017173206A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| IL302209B2 (en) | 2015-11-02 | 2024-06-01 | Blueprint Medicines Corp | Inhibitors of ret |
| KR102359735B1 (ko) | 2016-03-31 | 2022-02-08 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체 |
| DK3436435T3 (da) | 2016-03-31 | 2021-08-09 | Janssen Pharmaceuticals Inc | Substituerede indolderivater som inhibitorer af replikation af denguevirus |
| MX379439B (es) | 2016-04-01 | 2025-03-10 | Signal Pharm Llc | Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas. |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3013408A1 (en) | 2016-04-01 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| HUE054379T2 (hu) | 2017-05-22 | 2021-09-28 | Janssen Pharmaceuticals Inc | Helyettesített indolin-származékok mint a dengue vírus szaporodásának inhibitorai |
| WO2018215315A1 (en) | 2017-05-22 | 2018-11-29 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| WO2019070845A1 (en) | 2017-10-04 | 2019-04-11 | Celgene Corporation | COMPOSITIONS AND METHODS OF USING CIS-4- [2 - {[(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO} -8- (2,4,6-TRICHLOROANILINO) -9H-PURINE-9 yl] -1-methylcyclohexane-1-carboxamide |
| PT3773589T (pt) | 2018-04-03 | 2024-02-06 | Blueprint Medicines Corp | Inibidor de ret para utilização no tratamento de cancro com alteração de ret |
| WO2020033838A2 (en) * | 2018-08-10 | 2020-02-13 | Blueprint Medicines Corporation | Treatment of egfr-mutant cancer |
| EP3956033B1 (en) * | 2019-04-16 | 2024-12-11 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4061364A4 (en) * | 2019-11-20 | 2023-09-13 | Vivace Therapeutics, Inc. | HETEROARYL COMPOUNDS |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| KR102664454B1 (ko) * | 2021-08-03 | 2024-05-09 | 한국생명공학연구원 | 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용 |
| CN114681456A (zh) * | 2022-02-23 | 2022-07-01 | 中山大学附属第六医院 | Plx3397在结直肠癌的治疗中的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| WO2005063766A2 (en) * | 2003-12-23 | 2005-07-14 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2007030438A2 (en) * | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| US20090215744A1 (en) | 2005-11-18 | 2009-08-27 | Astrazeneca Ab | Solid Formulations |
| US7595401B2 (en) * | 2006-05-12 | 2009-09-29 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in cancer |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| NZ598071A (en) | 2006-10-27 | 2013-08-30 | Signal Pharm Llc | Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| EP2279731B1 (en) | 2008-04-23 | 2012-12-12 | Farmasierra Manufacturing, S.L. | Improved pharmaceutical composition containing ibuprofen and codeine |
| US20130034495A1 (en) | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US9466042B2 (en) | 2012-01-24 | 2016-10-11 | International Business Machines Corporation | Facilitating the design of information technology solutions |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| AU2015328414B2 (en) * | 2014-10-06 | 2020-03-19 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| CN115131834A (zh) * | 2015-08-13 | 2022-09-30 | 小米科技有限责任公司 | 移动设备及其屏幕模组、指纹采集方法、装置及电子设备 |
| MX379439B (es) * | 2016-04-01 | 2025-03-10 | Signal Pharm Llc | Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas. |
-
2017
- 2017-03-31 EP EP17776735.7A patent/EP3436018A4/en not_active Withdrawn
- 2017-03-31 JP JP2018551358A patent/JP7014731B2/ja active Active
- 2017-03-31 IL IL262007A patent/IL262007B2/en unknown
- 2017-03-31 EA EA201892229A patent/EA039392B1/ru unknown
- 2017-03-31 CA CA3018986A patent/CA3018986A1/en not_active Abandoned
- 2017-03-31 NZ NZ746554A patent/NZ746554A/en unknown
- 2017-03-31 CN CN201780021651.0A patent/CN109069512B/zh active Active
- 2017-03-31 US US15/475,899 patent/US10576085B2/en active Active
- 2017-03-31 WO PCT/US2017/025252 patent/WO2017173206A1/en not_active Ceased
- 2017-03-31 AU AU2017241837A patent/AU2017241837B2/en active Active
- 2017-03-31 BR BR112018070163A patent/BR112018070163A2/pt not_active Application Discontinuation
- 2017-03-31 MX MX2018011992A patent/MX379513B/es unknown
- 2017-03-31 SG SG10202009589UA patent/SG10202009589UA/en unknown
- 2017-03-31 SG SG11201808388QA patent/SG11201808388QA/en unknown
- 2017-03-31 KR KR1020187028514A patent/KR102356433B1/ko active Active
-
2018
- 2018-09-28 CL CL2018002787A patent/CL2018002787A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201808388QA (en) | 2018-10-30 |
| IL262007B2 (en) | 2023-04-01 |
| AU2017241837B2 (en) | 2021-07-22 |
| NZ746554A (en) | 2023-03-31 |
| CA3018986A1 (en) | 2017-10-05 |
| EA201892229A1 (ru) | 2019-03-29 |
| JP7014731B2 (ja) | 2022-02-01 |
| US10576085B2 (en) | 2020-03-03 |
| CN109069512B (zh) | 2022-06-14 |
| EP3436018A1 (en) | 2019-02-06 |
| EA039392B1 (ru) | 2022-01-21 |
| KR20180126497A (ko) | 2018-11-27 |
| KR102356433B1 (ko) | 2022-01-27 |
| WO2017173206A1 (en) | 2017-10-05 |
| CN109069512A (zh) | 2018-12-21 |
| BR112018070163A2 (pt) | 2019-01-29 |
| MX2018011992A (es) | 2019-01-24 |
| EP3436018A4 (en) | 2019-11-13 |
| US20170281633A1 (en) | 2017-10-05 |
| AU2017241837A1 (en) | 2018-10-25 |
| JP2019510066A (ja) | 2019-04-11 |
| IL262007B (en) | 2022-12-01 |
| CL2018002787A1 (es) | 2019-01-18 |
| SG10202009589UA (en) | 2020-10-29 |
| IL262007A (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| PH12020551760A1 (en) | Pyridazinones as parp7 inhibitors | |
| MX2020011907A (es) | Inhibidores de kras g12c para el tratamiento de cancer. | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| EA201890857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| AU2016256469A8 (en) | Methods for treating cancer | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| PH12018500423A1 (en) | Inhibitors of ezh2 | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2018008507A (es) | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). | |
| MX2021012096A (es) | Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo. | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| IL282692A (en) | Compounds derived from madrasin, a preparation and their uses for the treatment of cancer | |
| MX2017014463A (es) | Cabazitaxel y su uso para tratar cancer. | |
| PH12021552389A1 (en) | Quinoline derivatives and their use for the treatment of cancer | |
| MX2021009195A (es) | Metodos y composiciones para el tratamiento del cancer. |